Market Cap 1.59B
Revenue (ttm) 233.18M
Net Income (ttm) -321.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -137.90%
Debt to Equity Ratio 0.00
Volume 1,378,926
Avg Vol 1,735,664
Day's Range N/A - N/A
Shares Out 88.74M
Stochastic %K 12%
Beta 0.75
Analysts Strong Sell
Price Target $33.93

Latest News on TVTX

Travere Therapeutics to Present at Upcoming Investor Conferences

Nov 25, 2024, 4:30 PM EST - 4 months ago

Travere Therapeutics to Present at Upcoming Investor Conferences


Overlooked Stock: TVTX

Sep 9, 2024, 4:50 PM EDT - 7 months ago

Overlooked Stock: TVTX


Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30, 2024, 4:23 PM EDT - 7 months ago

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan